MONASH IVF GROUP LIMITED (MVF)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MVF - MONASH IVF GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 1.99
Index: ASX300 | ALL-ORDS

Monash IVF is an Australian provider of IVF, Ultrasound and genetic testing services throughout Australia and Asia. The company has been listed since 2014.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.45

19 Apr
2024

0.000

OPEN

$1.45

0.000

HIGH

$1.46

745,575

LOW

$1.43

TARGET
$1.563 7.8% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . CAJ . DOC . EBO . HLS . M7T . MDR . MPL . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
MVF: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx N/A 7.6 xxx
DPS (cps) xxx N/A 5.1 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 19.2 xxx
Dividend Yield xxx N/A 3.5% xxx
Div Pay Ratio(%) xxx N/A 66.9% xxx

Dividend yield today if purchased 3 years ago: 5.12%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

3.03

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 07/03 - ex-div 2.5c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx5.6
DPS All xxxxxxxxxxxxxxx4.4
Sales/Revenue xxxxxxxxxxxxxxx213.6 M
Book Value Per Share xxxxxxxxxxxxxxx70.1
Net Operating Cash Flow xxxxxxxxxxxxxxx38.0 M
Net Profit Margin xxxxxxxxxxxxxxx10.22 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx8.07 %
Return on Invested Capital xxxxxxxxxxxxxxx6.20 %
Return on Assets xxxxxxxxxxxxxxx5.40 %
Return on Equity xxxxxxxxxxxxxxx8.07 %
Return on Total Capital xxxxxxxxxxxxxxx9.70 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-7.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx6 M
Long Term Debt xxxxxxxxxxxxxxx94 M
Total Debt xxxxxxxxxxxxxxx100 M
Goodwill - Gross xxxxxxxxxxxxxxx255 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx8 M
Price To Book Value xxxxxxxxxxxxxxx1.63

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx27.8 M
Capex % of Sales xxxxxxxxxxxxxxx13.01 %
Cost of Goods Sold xxxxxxxxxxxxxxx150 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx28 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx2 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.9

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

26/02/2024

1

Overweight

$1.65

13.79%

Monash IVF's December-half top-line result outpaced consensus' and Morgan Stanley's forecasts by 5%, the company's market share growth outpacing peers as price increases kicked in across all domestic markets.

But underlying earnings proved a miss, margins sharply disappointing as staff and supplier costs rose along with a blow-out in fixed costs for new clinic infrastructure. The International business appears to have missed forecasts.

Management's maiden guidance met consensus forecasts but fell shy of Morgan Stanley's estimates.

The broker appreciates the company's balance sheet.

EPS forecasts fall -1% in FY24; rise 5% in FY25; and rise 4% in FY26. 

Overweight rating retained. Target price rises to $1.65 from $1.45 to reflect the company's market-share gains on outer years. Industry view: In line.

FORECAST
Morgan Stanley forecasts a full year FY24 dividend of 5.10 cents and EPS of 8.00 cents.
Morgan Stanley forecasts a full year FY25 dividend of 5.90 cents and EPS of 8.00 cents.

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

MVF STOCK CHART